Sustained release, comfort formulation for glaucoma therapy
AssigneeAlcon Laboratories, Inc.
InventorsRajni Jani, Robert G. Harris
Life of this patent
Estimating the term…
Abstract
Disclosed are nonstinging, sustained release ophthalmic formulations to control intraocular pressure in antiglaucoma therapy comprising a basic active, a cation exchange resin, and, inter alia, an acidic, mucomimetic polymer. Also disclosed are methods of treatment comprising administering such formulations topically to the eye when indicated for control and lowering of intraocular pressure.
Claims12
A sustained release ophthalmic pharmaceutical composition in the form of an aqueous gel, a pourable aqueous dispersion, or anhydrous salt, for controlling and lowering intraocular pressure comprising:
- a therapeutically effective amount of betaxolol;
- an amount of an anionic mucomimetic polymer having carboxylic acid functional groups which comprise from 2 to 7 carbon atoms per functional group and a molecular weight of from 50,000 to 6 million such that the composition in the form of an aqueous gel or pourable aqueous dispersion has a viscosity of about 1 to about 20,000 cps.;
- and sodium poly(styrenedivinylbenzene) sulfonic acid at a concentration of from about 0.05% to 10.0% by weight, the composition having a pH of from about 3.0 to 8.5.
A method of treatment for controlling and lowering intraocular pressure which comprises administering topically to the affected eye a pharmaceutical composition which includes:
- a therapeutically effective amount of betaxolol;
- an amount of an anionic mucomimetic polymer having carboxylic acid functional groups which comprise from 2 to 7 carbon atoms per functional group and a molecular weight of from 50,000 to 6 million such that the composition in the form of an aqueous gel or pourable aqueous dispersion has a viscosity of about 1 to about 20,000 cps.;
- and sodium poly(styrene-divinylbenzene) sulfonic acid at a concentration of from about 0.05% to 10.0% by weight, the composition having a pH of from about 3.0 to 8.5.
Dependencies are inferred from the claim text.